Create a treatment protocol document for IgE-lowering therapies
Reading File
Asking for Preferences
Finding Sources
Finding Sources
Searching PubMed
omalizumab IgE allergic asthma treatment guidelines
Searching the Web
IgE-lowering biologics allergic asthma treatment protocol 2024 2025 omalizumab tezepelumab dupilumab
Reading File
Reading File
Reading File
Reading Web Page
IgE-lowering therapy omalizumab tezepelumab dupilumab dosing eligibility criteria monitoring
Reading File
Finding Sources
Reading File
Reading File
Reading File
Running Command
Writing File
Running Command
Running Command
The protocol document is ready. Here's your download link:
IgE Lowering Therapy Protocol
PDF Document · PDF
What's in the Document
The PDF is a professionally formatted, 4-section, multi-page clinical protocol covering:
| Section | Content |
|---|---|
| 1. Overview | Purpose, scope, target disease areas |
| 2. IgE Pathway | Pathophysiology table: triggers → mediators → downstream effects |
| 3. Patient Selection | Standard therapy prerequisites + biomarker-guided eligibility table (GINA 2025) |
| 4. Dosing & Administration | Detailed drug sheets for omalizumab, dupilumab, and tezepelumab; note on anti-IL-5 agents |
| 5. GP Decision Pathway | 6-step structured workflow from diagnosis to monitoring |
| 6. Safety & Monitoring | Per-agent adverse effect table; anaphylaxis warning box |
| 7. Response Assessment | Criteria table: exacerbations, OCS dose, FEV1, FeNO, QoL |
| 8. Special Populations | Children, pregnancy, elderly, obesity, helminth-endemic regions |
| 9. Quick Reference | Full comparison table of all 5 biologics (target, dose, eligibility, AEs, indications) |
| 10. References | 10 citations including GINA 2025, Goodman & Gilman, Katzung, PubMed 2024–2026 |
Sources used: Goodman & Gilman's Pharmacological Basis (14th ed), Katzung's Basic & Clinical Pharmacology (16th ed), Fishman's Pulmonary Diseases, Janeway's Immunobiology (10th ed), GINA 2025 Severe Asthma Guide, and recent PubMed systematic reviews (PMIDs 41652440, 41934326).
Create a treatment protocol document for IgE-lowering therapies
Asking for Preferences
Reading File
Reading File
Finding Sources
Finding Sources
Searching PubMed
chronic urticaria omalizumab treatment guidelines
Searching the Web
chronic urticaria IgE biologic therapy protocol 2025 omalizumab dupilumab ligelizumab guidelines
Finding Sources
Finding Sources
Reading Web Page
chronic urticaria IgE therapy omalizumab dupilumab dosing eligibility diagnosis management stepwise protocol
Reading File
Reading File
Reading File
Reading File
Reading File
Running Command
Writing File
Running Command
Editing File
Running Command
Running Command
Running Command
Running Command
Your Word document is ready:
IgE CU Treatment Protocol
Word Document · DOCX
What's in the Document
A professionally formatted GP-focused Word protocol with a branded header/footer, coloured info boxes, and 10 sections:
| Section | Content |
|---|---|
| 1. Overview & Scope | Purpose, clinical scope, exclusions (HAE) |
| 2. Classification & Pathophysiology | CSU vs. CIndU classification table; IgE pathway narrative |
| 3. Diagnosis & Initial Assessment | Clinical criteria; recommended investigations table (CBC, ESR, thyroid, IgE, C4, biopsy); disease activity scoring tools (UAS7, UCT, CU-Q2oL, AAS7) |
| 4. Stepwise Treatment Algorithm | 5-step colour-coded escalation: antihistamine → up-dose → omalizumab → dupilumab → cyclosporine/specialist |
| 5. Drug Reference | Full tables for omalizumab and dupilumab (mechanism, dose, eligibility, evidence, AEs); emerging agents table (ligelizumab, tezepelumab, remibrutinib, barzolvolimab) |
| 6. Safety Monitoring | Per-agent adverse effect and monitoring table; anaphylaxis warning box |
| 7. Response Assessment | Timepoint-based follow-up table (baseline → 4–6 wks → 3 m → 6 m → 12 m); response definitions |
| 8. Special Populations | Children, adolescents, pregnancy, elderly, autoimmune CSU, inducible urticaria |
| 9. Quick Reference Summary | Single-table comparison of omalizumab, dupilumab, cyclosporine, remibrutinib |
| 10. References | 12 citations: Goldman-Cecil, Harrison's, Andrews', Katzung, EAACI 2022, StatPearls, and 5 recent PubMed papers (2025–2026) |
Key 2025–2026 updates included:
- Dupilumab FDA approval (April 2025) for CSU ≥12 years
- Remibrutinib Phase 3 positive data (PMID 41005705)
- Pediatric omalizumab meta-analysis (PMID 40545961)
- Network meta-analysis of biologics vs. immunomodulators in CU (PMID 40663028)
This is a shared conversation. Sign in to Orris to start your own chat.